Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Mark J. Shelton"'
Publikováno v:
Clinical Pharmacology in Drug Development. 11:1165-1176
Ripretinib is a switch control KIT kinase inhibitor approved for treatment of adults with advanced gastrointestinal stromal tumors who received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib and its active metabolite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f75aba95383a9b142b4a55f36b9cdf
https://doi.org/10.1002/cpdd.1110
https://doi.org/10.1002/cpdd.1110
Autor:
Edward J Mills, Jason A. Roberts, Alex Lepak, Debra Hanna, Mark J. Shelton, Kayla Ann Andrews, Craig R. Rayner, Lena E. Friberg, Patrick F. Smith, David Wesche, David R. Andes, Karen Rowland‐Yeo, Hartmut Derendorf, Virna J A Schuck, Thomas M. Polasek
Publikováno v:
Clinical Pharmacology and Therapeutics
Model-informed drug development (MIDD) has a long and rich history in infectious diseases. This review describes foundational principles of translational anti-infective pharmacology, including choice of appropriate measures of exposure and pharmacody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4da6a3ebd42760e80ec87464af056198
https://doi.org/10.1002/cpt.2198
https://doi.org/10.1002/cpt.2198
Autor:
Julie Meade, Xiaoyan Li, Mark J. Shelton, Cherie Taglienti, Constance Barysauskas, Rodrigo Ruiz-Soto, J. Wang
Publikováno v:
Cancer Research. 81:CT132-CT132
Ripretinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with 3 or more kinase inhibitors, including imatinib. In a phase 1 study in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd70457ee1f76e0fe991d51e9bd6e6b6
https://doi.org/10.1158/1538-7445.am2021-ct132
https://doi.org/10.1158/1538-7445.am2021-ct132
Autor:
Yu Lou, Mark J. Shelton, Geoffrey J. Yuen, Susan L. Ford, Julie Borland, Sherene S. Min, Ya-Chi Chen
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:534-538
Rifabutin (RFB) is administered for treatment of tuberculosis and Mycobacterium avium complex infection, including use for patients coinfected with human immunodeficiency virus (HIV). Increased systemic exposure to RFB and its equipotent active metab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f984f61234a63ec4e35b3098801e688e
https://doi.org/10.1128/aac.00724-07
https://doi.org/10.1128/aac.00724-07
Autor:
Keith A. Pappa, Yu Lou, Mary Beth Wire, Andrew D. Luber, Mark J. Shelton, Col Study Team, Peter Ruane, C. Tracey Lancaster
Publikováno v:
Antimicrobial Agents and Chemotherapy. 51:560-565
Once-daily (QD) fosamprenavir (FPV) at 1,400 mg boosted with low-dose ritonavir (RTV) at 200 mg is effective when it is used in combination regimens for the initial treatment of human immunodeficiency virus infection. Whether a lower RTV boosting dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46346b502b0bbaf180ac9bfe2df39a8
https://doi.org/10.1128/aac.00560-06
https://doi.org/10.1128/aac.00560-06
Autor:
Mary Beth Wire, Zhengyu G. Xue, Geoffrey J. Yuen, Susan L. Ford, Yu Lou, Mark J. Shelton, Julie Borland, Sherene S. Min
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 42:61-67
Objectives: To evaluate the drug interaction between fosamprenavir (FPV) and esomeprazole (ESO) after repeated doses in healthy adults. Methods: Subjects received ESO 20 mg once daily (qd) for 7 days followed by either ESO 20 mg qd + FPV 1400 mg twic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a76d82581e10275285f5e6a71f73f976
https://doi.org/10.1097/01.qai.0000219770.97303.43
https://doi.org/10.1097/01.qai.0000219770.97303.43
Publikováno v:
Antimicrobial Agents and Chemotherapy. 50:928-934
High-dose combinations of fosamprenavir (FPV) and ritonavir (RTV) were evaluated in healthy adult subjects in order to select doses for further study in multiple protease inhibitor (PI)-experienced patients infected with human immunodeficiency virus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db30c4c9570fd38e2c6f4190db1d2ad7
https://doi.org/10.1128/aac.50.3.928-934.2006
https://doi.org/10.1128/aac.50.3.928-934.2006
Publikováno v:
Clinical Pharmacokinetics. 45:137-168
Fosamprenavir is one of the most recently approved HIV-1 protease inhibitors (PIs) and offers reductions in pill number and pill size, and omits the need for food and fluid requirements associated with the earlier-approved HIV-1 PIs. Three fosamprena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3f8ff602a272aafa7cad7d55d12329a
https://doi.org/10.2165/00003088-200645020-00002
https://doi.org/10.2165/00003088-200645020-00002
Autor:
Steven R. Cox, Andrew A. Della-Coletta, Mark J. Shelton, Gene D. Morse, John Clarke Adams, Ross G. Hewitt
Publikováno v:
Antimicrobial Agents and Chemotherapy. 47:1694-1699
To evaluate the pharmacokinetic effect of adding delavirdine mesylate to the antiretroviral regimens of human immunodeficiency virus (HIV)-infected patients stabilized on a full dosage of ritonavir (600 mg every 12 h), 12 HIV-1-infected subjects had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8475f871809fb1ad4a273f2e83847b1
https://doi.org/10.1128/aac.47.5.1694-1699.2003
https://doi.org/10.1128/aac.47.5.1694-1699.2003
Autor:
Mark J. Shelton, James H. Chambers, Ross G. Hewitt, Gene D. Morse, John M. Adams, Steve R. Cox
Publikováno v:
The Journal of Clinical Pharmacology. 43:171-179
To determine the impact of gastric hypoacidity and acidic beverages on delavirdine mesylate pharmacokinetics in HIV-infected subjects, matched subjects with (n = 11) and without (n = 10) gastric hypoacidity received delavirdine 400 mg tid with either
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01d2c1f805fc7831997dc4ff2ea3fe2
https://doi.org/10.1177/0091270002239826
https://doi.org/10.1177/0091270002239826